Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 [68Ga]Ga-DOTA-FAPI-04 PET/CT imaging in a case of prostate cancer with shoulder arthritis.

Literature DB >> 32901354

[⁶⁸Ga]Ga-DOTA-FAPI-04 PET/CT imaging in a case of prostate cancer with shoulder arthritis.

Tingting Xu^1,2,3, Yan Zhao^1,2,3, Haoyuan Ding^1,2,3, Liang Cai^1,2,3, Zhijun Zhou^1,2,3, Zhenyu Song⁴, Yue Chen^5,6,7.

Abstract

Entities: Chemical Disease

Year: 2020 PMID： 32901354 DOI： 10.1007/s00259-020-05028-x

Source DB: PubMed Journal: Eur J Nucl Med Mol Imaging ISSN： 1619-7070 Impact factor: 9.236

Keyword Cloud
Cited

× No keyword cloud information.

7 in total

1. The potential utility of [⁶⁸ Ga]Ga-DOTA-FAPI-04 as a novel broad-spectrum oncological and non-oncological imaging agent-comparison with [¹⁸F]FDG.

Authors: Lianjun Lan; Hanxiang Liu; Yingwei Wang; Jia Deng; Dengsai Peng; Yue Feng; Li Wang; Yue Chen; Lin Qiu
Journal: Eur J Nucl Med Mol Imaging Date: 2021-08-19 Impact factor: 9.236

2. Distinguishing Benign and Malignant Findings on [⁶⁸ Ga]-FAPI PET/CT Based on Quantitative SUV Measurements.

Authors: M Dabir; E Novruzov; K Mattes-György; M Beu; K Dendl; C Antke; S A Koerber; M Röhrich; C Kratochwil; J Debus; U Haberkorn; F L Giesel
Journal: Mol Imaging Biol Date: 2022-08-23 Impact factor: 3.484

Review 3. Clinical summary of fibroblast activation protein inhibitor-based radiopharmaceuticals: cancer and beyond.

Authors: Mengting Li; Muhsin H Younis; Yongxue Zhang; Weibo Cai; Xiaoli Lan
Journal: Eur J Nucl Med Mol Imaging Date: 2022-01-31 Impact factor: 10.057

4. Comparison of the Relative Diagnostic Performance of [⁶⁸Ga]Ga-DOTA-FAPI-04 and [¹⁸F]FDG PET/CT for the Detection of Bone Metastasis in Patients With Different Cancers.

Authors: Junhao Wu; Yingwei Wang; Taiping Liao; Zijuan Rao; Weidong Gong; Lei Ou; Yue Chen; Chunyin Zhang
Journal: Front Oncol Date: 2021-09-17 Impact factor: 6.244

[⁶⁸Ga]Ga-DOTA-FAPI-04 PET/CT imaging in a case of prostate cancer with shoulder arthritis.

1. The potential utility of [⁶⁸ Ga]Ga-DOTA-FAPI-04 as a novel broad-spectrum oncological and non-oncological imaging agent-comparison with [¹⁸F]FDG.

2. Distinguishing Benign and Malignant Findings on [⁶⁸ Ga]-FAPI PET/CT Based on Quantitative SUV Measurements.

Review 3. Clinical summary of fibroblast activation protein inhibitor-based radiopharmaceuticals: cancer and beyond.

4. Comparison of the Relative Diagnostic Performance of [⁶⁸Ga]Ga-DOTA-FAPI-04 and [¹⁸F]FDG PET/CT for the Detection of Bone Metastasis in Patients With Different Cancers.

5. Could Fibroblast Activation Protein (FAP)-Specific Radioligands Be Considered as Pan-Tumor Agents?

6. Emerging Role of FAPI PET Imaging for the Assessment of Benign Bone and Joint Diseases.

Review 7. FAPI PET/CT in the Diagnosis of Abdominal and Pelvic Tumors.

[68Ga]Ga-DOTA-FAPI-04 PET/CT imaging in a case of prostate cancer with shoulder arthritis.

1. The potential utility of [68 Ga]Ga-DOTA-FAPI-04 as a novel broad-spectrum oncological and non-oncological imaging agent-comparison with [18F]FDG.

2. Distinguishing Benign and Malignant Findings on [68 Ga]-FAPI PET/CT Based on Quantitative SUV Measurements.

Review 3. Clinical summary of fibroblast activation protein inhibitor-based radiopharmaceuticals: cancer and beyond.

4. Comparison of the Relative Diagnostic Performance of [68Ga]Ga-DOTA-FAPI-04 and [18F]FDG PET/CT for the Detection of Bone Metastasis in Patients With Different Cancers.

5. Could Fibroblast Activation Protein (FAP)-Specific Radioligands Be Considered as Pan-Tumor Agents?

6. Emerging Role of FAPI PET Imaging for the Assessment of Benign Bone and Joint Diseases.

Review 7. FAPI PET/CT in the Diagnosis of Abdominal and Pelvic Tumors.

[⁶⁸Ga]Ga-DOTA-FAPI-04 PET/CT imaging in a case of prostate cancer with shoulder arthritis.

1. The potential utility of [⁶⁸ Ga]Ga-DOTA-FAPI-04 as a novel broad-spectrum oncological and non-oncological imaging agent-comparison with [¹⁸F]FDG.

2. Distinguishing Benign and Malignant Findings on [⁶⁸ Ga]-FAPI PET/CT Based on Quantitative SUV Measurements.

4. Comparison of the Relative Diagnostic Performance of [⁶⁸Ga]Ga-DOTA-FAPI-04 and [¹⁸F]FDG PET/CT for the Detection of Bone Metastasis in Patients With Different Cancers.